Could Immuron’s (ASX:IMC) traveller’s diarrhoea treatment be used to fight COVID-19?
Immuron’s (IMC) share price has more than doubled on the news a drug used in its traveller’s diarrhoea formulation neutralises activity aginst the COVID-19 virus.
https://themarketherald.com.au/could-immurons-asximc-travellers-diarrhoea-treatment-be-used-to-fight-covid-19-2020-07-21/
Filter by Year:
- Immuron partnering with Walter Reid Army Institute of Research to test Travelan against Shigella, ETEC, Vibrio cholerae and Campylobacter jejuni isolates (2020, WRAIR's Investigator's Dispatch)
- Immuron (ASX:IMC) enters research agreement with Monash University
- Walter Reid Army Institute of Research 2019 Year in Review
- Immuron reveals anti-COVID potential, raises $28 million
- Diarrhea: A major health issue for Americans travelling abroad
- Could Immuron’s (ASX:IMC) traveller’s diarrhoea treatment be used to fight COVID-19?
This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.
